Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pentamycin - Lumavita

Drug Profile

Pentamycin - Lumavita

Alternative Names: Antibiotic A-246; Cogomycin; FemiFect; Fungichromin; Lagosin; LMV-602; N-Pent; NP 401; NP 402; NP 403; NP 404; Pruri-Ex; SPK-0602

Latest Information Update: 11 Mar 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Necura Pharmaceuticals AG
  • Developer Lumavita; Necura Pharmaceuticals AG
  • Class Anti-infectives; Macrolides; Polyenes; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Vaginitis
  • Discontinued Cancer; Candidiasis; Intestinal infections; Skin and soft tissue infections

Most Recent Events

  • 11 Mar 2015 Discontinued - Preclinical for Vaginitis (LMV 602) in Switzerland (Vaginal)
  • 11 Mar 2015 No recent reports on development identified - Preregistration for Vaginitis in Asia, Commonwealth of Independent States, Latin America and North Africa (Vaginal)
  • 11 Mar 2015 No recent reports on development identified - Registered for Vaginitis in Switzerland (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top